EDMONTON, Alberta, March 27, 2015 – BioNeutra Global Corporation (CSE: BGA) (“BioNeutra” or the “Company“) is pleased to announce that, further to its press release of February 12, 2015, it has closed on the full 3,300,000 units (“Units”) at a price of $0.30 per Unit for gross proceeds of $990,000 by way of a private placement (the “Private Placement”). Each Unit is comprised of one (1) common share (“Common Share”) and one (1) Common Share purchase warrant (a “Warrant”). Each Warrant entitles the holder to purchase one (1) additional Common Share at a price of $0.50 per Common Share for a period of thirty-six (36) months following the date of closing, provided that if after four months and one day following the closing date the closing price of the common shares is equal to or exceeds $1.00 for twenty (20) consecutive trading days, then the warrants shall accelerate to expire on the date which is thirty (30) days following the date a press release is issued by BioNeutra announcing the reduced warrant term or the date that written notice has been given to the warrantholder.
BioNeutra intends to use the proceeds from the Private Placement for general working capital.
Pursuant to applicable securities laws, the securities issued under the Private Placement are subject to a minimum four-month hold period from the time of closing of the Private Placement.
No bonus, finder’s fee, commission or agents options have been paid in connection with the closing of the Private Placement.
Certain insiders of the Corporation have acquired Units under the Private Placement. Any such participation would constitute a “related party transaction” within the meaning of Multilateral Instrument 61-101 (“MI 61-101”), but are otherwise exempt from the formal valuation and minority approval requirements of MI 61-101.
Additional details regarding the Private Placement can be found in the final Form 9 filed on March 18, 2015 in accordance with the rules of the Canadian Securities Exchange, a copy of which is accessible at www.cnsx.ca under the Corporation’s profile.
For further information contact:
BioNeutra Global Corporation
Bill Smith, Chairman & Senior Vice President
T: (780) 466-1481 x 117